KINASET THERAPEUTICS
Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.
KINASET THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Founded:
2020-01-01
Address:
Medfield, Massachusetts, United States
Country:
United States
Total Employee:
251+
Status:
Active
Contact:
(508) 858-5810
Total Funding:
41.5 M USD
Similar Organizations
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Gimv
Gimv investment in Series A - Kinaset Therapeutics
Atlas Venture
Atlas Venture investment in Series A - Kinaset Therapeutics
5AM Ventures
5AM Ventures investment in Series A - Kinaset Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-07 | Kinaset Therapeutics Appoints Christopher OโBrien, MD, PhD, FCCP, as Chief Medical Officer |
More informations about "Kinaset Therapeutics"
About Us - Kinaset Therapeutics
About Us Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. Our lead clinical candidate, frevecitinib (KN-002), is โฆSee details»
Kinaset Therapeutics - Crunchbase Company Profile
Kinaset Therapeutics is a biopharma company that focuses on advancement of โฆSee details»
Kinaset Therapeutics, Inc. (Kinaset Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธ โฆ
May 7, 2025 About Kinaset Therapeutics, Inc. Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. With โฆSee details»
Gimv is founding investor of Kinaset Therapeutics in a USD 40m โฆ
Gimv invests in Kinaset Therapeutics alongside 5AM Ventures and Atlas Venture in a USD 40m Series A round to support the clinical development of KN-002, a novel dry powder inhalable pan โฆSee details»
Kinaset Therapeutics Launches with a $40M Series A Financing to โฆ
Nov 30, 2020 Therefore, additional therapeutics to support these non-eosinophilic patients represent a significant need in asthma control. About Kinaset Therapeutics, Inc.See details»
Kinaset Therapeutics
Mar 12, 2022 Pharma's Almanac: Nice Insight's Content CommunityKinaset Therapeutics Drug Discovery & Development Overview Kinaset Therapeutics is a biopharmaceutical company โฆSee details»
Kinaset Therapeutics - 2025 Company Profile & Team - Tracxn
Jun 14, 2025 Explore Kinaset Therapeutics' in-depth company profile, including funding details, key investors, leadership, and competitors.See details»
Kinaset Therapeutics - LinkedIn
At Kinaset Therapeutics, we intend to develop novel respiratory therapeutics that can positively impact people affected by intractable diseases. Our novel lead asset โฆSee details»
Kinaset Therapeutics, Inc. - Executive Bio, Top Executies, and ...
Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. It engages in developing novel respiratory therapeutics that can โฆSee details»
Kinaset Therapeutics: Revenue, Worth, Valuation & Competitors 2024
Kinaset Therapeutics is a Pharmaceuticals related company founded in 2020 and based in Boston with 16 employees an estimated revenue of $3.2M, and. It has 10 competitors including Imaging โฆSee details»
Kinaset Therapeutics - TwoInstitute
About Kinaset Therapeutics is Drug Discovery in United States that focus on lead asset business. Founded in 2020. They cover business area such as developer, respiratory drug development, โฆSee details»
Kinaset Therapeutics - VentureRadar
Kinaset Therapeutics intends to develop novel therapeutics that can positively impact people affected by intractable diseases, including severe asthma. The firm's novel lead asset and experienced โฆSee details»
Kinaset Therapeutics debuts with $40M for pan-JAK asthma med
Nov 30, 2020 With Vecturaโs help, Kinaset will develop KN-002, an inhalable small molecule, to provide a treatment option for patients with severe non-eosinophilic asthma and offer patients โฆSee details»
Kinaset Therapeutics - Products, Competitors, Financials, Employees ...
About Kinaset Therapeutics Kinaset Therapeutics focuses on developing inhaled therapeutics for respiratory diseases within the pharmaceutical industry. The company is working on its lead โฆSee details»
Kinaset Therapeutics, Inc. Company Profile - Dun & Bradstreet
What year was Kinaset Therapeutics, Inc. started? How much does Kinaset Therapeutics, Inc. generate in sales? Who are Kinaset Therapeutics, Inc.'s top competitors?See details»
Kinaset Therapeutics Information - RocketReach
Kinaset Therapeutics is a Pharmaceutical Manufacturing company located in Boston, Massachusetts with 12 employees. Find top employees, contact details and business statistics at RocketReach.See details»
Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical ...
BOSTON, September 04, 2024--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced two oral ...See details»
KINASET THERAPEUTICS LTD filing history - Find and update โฆ
Apr 7, 2025 KINASET THERAPEUTICS LTD - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, โฆSee details»
Kinaset Therapeutics Launches With $40 Million Series A to Advance ...
Nov 30, 2020 Biotechnology startup Kinaset Therapeutics Inc. has launched with $40 million in venture financing to develop a drug that could make life easier for people with severe asthma. โฆSee details»
Kinaset Therapeutics to Share Outcomes from the Phase 1 Clinical ...
Sep 4, 2024 About Kinaset Therapeutics, Inc. Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. With โฆSee details»